Follow-up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment.

Recruiting now

Conditions studied: Cutaneous Squamous Cell Carcinoma (CSCC)

In brief

In the context where advanced cutaneous squamous cell carcinoma (cSCC) is currently a public health issue due to its increasing incidence and where its management is rapidly evolving, it is essential to characterize and monitor changes in therapeutic strategies for patients requiring systemic treatment with adjuvant/neoadjuvant or curative setting. The overall objective of this study is to describe the long-term, real-life management of patients with cSCC requiring systemic therapy, including their clinical characteristics as well as treatment effectiveness and safety. To achieve this aim, the project is based on the establishment of a French national database of patients with cSCC receiving systemic therapy. This is a non-interventional multicenter study involving approximately 30 centers from the French Cutaneous Oncology Group (GCC), including a retrospective phase (from January 2020 for initiation of first-line systemic therapy) followed by a prospective phase. Time perspective is Retrospective and Prospective

Key facts

Study ID

NCT07606508

Run by

University Hospital, Lille

People needed

1500

Starts

2021-07-09

Expected to finish

2036-07-15

Last updated by the study team

2026-05-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a diagnosis of primary cutaneous squamous cell carcinoma initiating first-line systemic therapy, whether administered with curative, adjuvant, or neoadjuvant intent.
• Male or female patients.
• Age ≥18 years.
• No documented objection to participation in the study.

You may not qualify if…

• Patients who refuse to participate in the study or who object to the collection or processing of their personal data.
• Initiation of systemic therapy prior to 2020.
• Patients not requiring systemic therapy.
• More than one line of systemic therapy at the time of inclusion.
• Patients under legal guardianship or curatorship.
• Individuals deprived of liberty.
• lack of health insurance coverage.

Where it is running

• CHRU de Nancy — Vandœuvre-lès-Nancy, France (enrolling)
• Centre Hospitalier Régional d'Orléans — Annecy, France (enrolling)
• CHRU Besançon — Besançon, France (enrolling)
• Centre Hospitalier de Blois — Blois, France (enrolling)
• Hôpital Avicenne — Bobigny, France (enrolling)
• Hôpital Saint André, — Bordeaux, France (enrolling)
• Hôpital Ambroise Paré — Boulogne-Billancourt, France (enrolling)
• Hôpital Bichat-Claude-Bernard — Paris, France (enrolling)
• Hôpital St Louis — Paris, France (enrolling)
• CHU Charles Nicolle — Rouen, France (enrolling)
• Institut de Cancérologie de l'Ouest — Saint-Herblain, France (enrolling)
• Centre Hospitalier de Valence — Valence, France (enrolling)
• CHRU de Tours — Chambray-lès-Tours, France (enrolling)
• CHU Estaing — Clermont-Ferrand, France (enrolling)
• CHU Henri Mondor — Créteil, France (enrolling)
• CHU Dijon Bourgogne — Dijon, France (enrolling)
• Centre Hospitalier Le Mans — Le Mans, France (enrolling)
• CHU Lille — Lille, France (enrolling)
• CHU Dijon Bourgogne — Lyon, France (enrolling)
• Hôpital de la Timone — Marseille, France (enrolling)
• CHRU Montpellier Hôpital Saint Eloi — Montpellier, France (enrolling)
• CHU Nantes — Nantes, France (enrolling)
• CHU de Nice — Nice, France (enrolling)
• Centre Hospitalier Régional d'Orléans — Orléans, France (enrolling)
• CHU de Caen — Caen, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.